参 考 文 献
［1] LEMKES J S，JANSSENS G N，VAN DER HOEVEN N W，et al. Coronary angiography after cardiac arrest without STSegment elevation［J］. N Engl J Med，2019，380（15）：1397-1407.
［2] MEHTA S R，WOOD D A，STOREY R F，et al. Complete revascularization with multivessel PCI for myocardial infarction［J］.N Engl J Med，2019，381（15）：1411-1421.
［3] MARON D J，HOCHMAN J S，REYNOLDS H R，et al. Initial Invasive or conservative strategy for stable coronary disease［J］.N Engl J Med，2020，382（15）：1395-1407.
［4] STONE G W，KAPPETEIN A P，SABIK J F，et al. Five-year outcomes after PCI or CABG for left main coronary disease［J］.N Engl J Med，2019，381（19）：1820-1830.
［5] HOLM N R，MAKIKALLIO T，LINDSAY M M，et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis：updated 5-year outcomes from the randomised，non-inferiority NOBLE trial［J］. Lancet.，2020，395（10219）：191-199.
［6] THUIJS D，KAPPETEIN A P，SERRUYS P W，et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease：10-year follow-up of the multicentre randomised controlled SYNTAX trial［J］. Lancet.，2019，394（10206）：1325-1334.
［7] PARK D W，AHN J M，PARK H，et al. Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease：Extended Follow-Up of the PRECOMBAT Trial［J］. Circulation，2020，141（18）：1437-1446.
［8] CHEN X，LI X，ZHANG J J，et al. 3-Year outcomes of the DKCRUSH-V Trial comparing DK Crush with provisional stenting for left main bifurcation lesions［J］. JACC Cardiovasc Interv，2019，12（19）：1927-1937.
［9] DOU K，ZHANG D，PAN H，et al. Active SB-P versus conventional approach to the protection of high-risk side Branches：The CIT-RESOLVE Trial［J］. JACC Cardiovasc Interv，2020，13（9）：1112-1122.
［10] DI GIOIA G，SONCK J，FERENC M，et al. Clinical outcomes following coronary bifurcation PCI Techniques：A Systematic Review and Network Meta-Analysis comprising 5 711 patients［J］. JACC Cardiovasc Interv，2020，13（12）：1432-1444.
［11] ZHANG J J，YE F，XU K，et al. Multicentre，randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions：the DEFINITION Ⅱ trial［J］. Eur Heart J，2020，41（27）：2523-2536.
［12] BRILAKIS E S，MASHAYEKHI K，TSUCHIKANE E，et al. Guiding principles for chronic total occlusion percutaneous coronary intervention［J］. Circulation，2019，140（5）：420-433.
［13] LEE S W，LEE P H，AHN J M，et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion［J］. Circulation，2019；139（14）：1674-1683.
［14] BUITEN R A，PLOUMEN E H，ZOCCA P，et al. Outcomes in patients treated with Thin-strut，very thin-strut，or ultrathinstrut drug-eluting stents in small coronary vessels：a prespecified analysis of the randomized BIO-RESORT Trial［J］. JAMA Cardiol，2019，4（7）：659-669.
［15] GIACOPPO D，ALFONSO F，XU B，et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis：a comprehensive，collaborative，individual patient data meta-analysis of 10 randomized clinical trials（DAEDALUS study）［J］. Eur Heart J，2019，11：ehz594.
［16] MEHRAN R，BABER U，SHARMA S K，et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI［J］. N Engl J Med，2019，381（21）：2032-2042.
［17] HAHN J Y，SONG Y B，OH J H，et al. Effect of P2Y12 Inhibitor Monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention：The SMART-CHOICE Randomized Clinical Trial［J］.JAMA.，2019，321（24）：2428-2437.
［18] WATANABE H，DOMEI T，MORIMOTO T，et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI：The STOPDAPT-2 Randomized Clinical Trial［J］. JAMA，. 2019，321（24）：2414-2427.
［19] KIM B K，HONG S J，CHO Y H，et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome：The TICO Randomized Clinical Trial［J］. JAMA.，2020，323（23）：2407-2416.
［20] FRANZONE A，MCFADDEN E，LEONARDI S，et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting［J］. J Am Coll Cardiol，2019，74（18）：2223-2234.
［21] O'DONOGHUE M L，MURPHY S A，SABATINE M S. The safety and efficacy of aspirin discontinuation on a background of a p2y12 inhibitor in patients after percutaneous coronary intervention：a systematic review and meta-Analysis［J］.Circulation，2020，142（6）：538-545.
［22] XUE H J，SHI J，LIU B，et al. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS［J］.Platelets，2016，27（5）：440-445.
［23] HE M，LIU B，SUN D，et al. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease：A randomized，single-blind，crossover clinical study［J］. Int J Cardiol，2016，215：209-213.
［24] SHI J，HE M，WANG W，et al. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease：a retrospective multicenter study（SUPERIOR）［J］. Platelets，2020：1-10.
［25] LOPES R D，HEIZER G，ARONSON R，et al. Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation［J］. N Engl J Med，2019，380（16）：1509-1524.
［26] VRANCKX P，VALGIMIGLI M，ECKARDT L，et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation（ENTRUST-AF PCI）：a randomised，open-label，phase 3b trial［J］. Lancet.，2019，394（10206）：1335-1343.
［27] GAO X F，WANG Z M，WANG F，et al. Intravascular ultrasound guidance reduces cardiac death and coronary revascularization in patients undergoing drug-eluting stent implantation：results from a meta-analysis of 9 randomized trials and 4724 patients［J］. Int J Cardiovasc Imaging，2019，35（2）：239-247.
［28] HONG S J，MINTZ G S，AHN C M，et al. Effect of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation：5-Year Follow-Up of the IVUS-XPL Randomized Trial［J］. JACC Cardiovasc Interv，2020，13（1）：62-71.
［29] BURZOTTA F，LEONE A M，AURIGEMMA C，et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis：A Single-Center Trial［J］. JACC Cardiovasc Interv，2020，13（1）：49-58.
［30] ADAMSON P D，WILLIAMS M C，DWECK M R，et al. Guiding therapy by coronary CT angiography improves outcomes in patients with stable chest pain［J］. J Am Coll Cardiol，2019，74（16）：2058-2070.
［31] DRIESSEN R S，DANAD I，STUIJFZAND W J，et al. Comparison of coronary computed tomography angiography，fractional flow reserve，and perfusion imaging for ischemia diagnosis［J］. J Am Coll Cardiol，2019，73（2）：161-173.
［32] SHARMA A，COLES A，SEKARAN N K，et al. Stress Testing versus CT angiography in patients with diabetes and suspected coronary artery disease［J］. J Am Coll Cardiol，2019，73（8）：893-902.
［33] KWONG R Y，GE Y，STEEL K，et al. Cardiac magnetic resonance stress perfusion imaging for evaluation of patients with chest pain［J］. J Am Coll Cardiol，2019，74（14）：1741-1755.
［34] NAGEL E，GREENWOOD J P，MCCANN G P，et al. Magnetic resonance perfusion or fractional flow reserve in coronary disease［J］. N Engl J Med，2019，380（25）：2418-2428.